NASDAQ$LQDA
Liquidia Corporation · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Liquidia Corporation reported Q2 2025 results including the first product sales of YUTREPIA following FDA approval.
Liquidia reported total revenue of $8.8 million for the quarter, driven by initial YUTREPIA product sales of $6.5 million and service revenue of $2.3 million from the Sandoz promotion agreement. The company recorded a net loss of $41.6 million and ended the quarter with $173.4 million in cash and cash equivalents. YUTREPIA was approved by the FDA on May 23, 2025 and commercially launched on June 2, 2025.
- YUTREPIA received FDA approval on May 23, 2025 and generated $6.5 million in product sales during its first partial quarter on the market.
- Total revenue reached $8.8 million, up from $3.7 million in the prior-year quarter, reflecting the addition of YUTREPIA sales.
- Net loss widened to $41.6 million as the company invested in commercialization infrastructure and ongoing litigation.
- Cash position remained strong at $173.4 million, supporting operations and minimum covenant requirements for at least the next twelve months.
Headline financials
Revenue & EPS history
Liquidia · Revenue · Quarterly
$8.84M
Revenue by segment
Liquidia · $8.84M total across 2 segments · Q2 2025
- YUTREPIA$6.52M—73.7%
- Promotion Agreement$2.32M—26.3%
Forward guidance
Management expects continued investment in YUTREPIA commercialization while maintaining sufficient liquidity for at least the next twelve months.
Tailwinds
- Cash and cash equivalents of $173.4 million support operations and debt covenants for at least twelve months.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
+3.4%
Avg return
Earnings day
+5.4%
Avg return
5 days after
+3.5%
Avg return
30 days after
60%
18 / 30 earnings
Positive
+31.8%
Q2 2022
Best reaction
-13.3%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +25.4% | +34.5% | +54.1% | |
| Q4 2025 | +0.4% | +12.9% | +9.6% | |
| Q3 2025 | +8.8% | +7.1% | +38.5% | |
| Q1 2025 | -1.0% | +3.0% | +16.8% | |
| Q4 2024 | +1.2% | +6.2% | -6.9% | |
| Q3 2024 | -5.6% | -7.6% | +2.7% | |
| Q2 2024 | +2.9% | +10.4% | -17.7% | |
| Q1 2024 | -0.8% | +5.4% | +10.4% | |
| Q4 2023 | +9.6% | +11.3% | -0.2% | |
| Q3 2023 | -1.0% | -4.4% | +9.8% | |
| Q2 2023 | -6.3% | -8.9% | -7.5% | |
| Q1 2023 | +5.0% | +7.8% | +26.1% | |
| Q4 2022 | +13.5% | +13.2% | +6.3% | |
| Q3 2022 | +0.8% | -0.4% | +14.6% | |
| Q2 2022 | +31.8% | +34.5% | +9.9% | |
| Q1 2022 | +7.7% | +21.9% | -17.0% | |
| Q4 2021 | +11.2% | +9.7% | -17.8% | |
| Q3 2021 | +9.9% | +9.7% | +3.1% | |
| Q2 2021 | -0.8% | +11.8% | +16.4% | |
| Q1 2021 | -0.7% | +0.0% | -0.7% | |
| Q4 2020 | -7.4% | -6.6% | +2.2% | |
| Q3 2020 | +0.7% | -12.7% | -36.9% | |
| Q2 2020 | -13.3% | -8.5% | -23.3% | |
| Q1 2020 | +8.0% | +8.7% | +13.4% | |
| Q4 2019 | -1.5% | +1.7% | +54.5% | |
| Q3 2019 | +5.2% | +0.6% | +6.4% | |
| Q2 2019 | +6.4% | -0.7% | -40.6% | |
| Q1 2019 | -3.0% | -0.4% | +2.6% | |
| Q4 2018 | +3.0% | +3.1% | -43.8% | |
| Q3 2018 | -9.2% | -1.3% | +19.4% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro